Aerovate Therapeutics, Inc. (AVTE): Price and Financial Metrics

Aerovate Therapeutics, Inc. (AVTE): $22.85

-0.84 (-3.55%)

POWR Rating

Component Grades













Add AVTE to Watchlist
Sign Up

Industry: Biotech



in industry

AVTE Stock Price Chart Interactive Chart >

Price chart for AVTE

AVTE Price/Volume Stats

Current price $22.85 52-week high $30.79
Prev. close $23.69 52-week low $8.33
Day low $22.59 Volume 29,503
Day high $24.23 Avg. volume 90,635
50-day MA $23.51 Dividend yield N/A
200-day MA $18.58 Market Cap 557.77M

Aerovate Therapeutics, Inc. (AVTE) Company Bio

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

AVTE Latest News Stream

Event/Time News Detail
Loading, please wait...

AVTE Latest Social Stream

Loading social stream, please wait...

View Full AVTE Social Stream

Latest AVTE News From Around the Web

Below are the latest news stories about AEROVATE THERAPEUTICS INC that investors may wish to consider to help them evaluate AVTE as an investment opportunity.

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are ex

Yahoo | January 23, 2023

Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

In this article we are going to estimate the intrinsic value of Aerovate Therapeutics, Inc. ( NASDAQ:AVTE ) by taking...

Yahoo | December 31, 2022

12 Best Performing Biotech Stocks in 2022

In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]

Yahoo | December 29, 2022

Aerovate Therapeutics Inc. (NASDAQ:AVTE) Declines -135.40% In 2022; Are Investors Attracted By Its $26.00 Price?

In last trading session, Aerovate Therapeutics Inc. (NASDAQ:AVTE) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $26.00 trading at $0.35 or 1.36% at ring of the bell on the day assigns it a market valuation of $627.64M. That closing price of AVTE’s stock is … Aerovate Therapeutics Inc. (NASDAQ:AVTE) Declines -135.40% In 2022; Are Investors Attracted By Its $26.00 Price? Read More »

Marketing Sentinel | December 17, 2022

JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) fell 23% to $8.31. The Lion Electric Company (NYSE: LEV ) declined 14.5% to $2.2810. Lion Electric reported pricing of 19,685,040 unit offering at $2.54 per unit. Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) dropped 11.5% to $27.00. Aerovate Therapeutics, last month, posted a Q3 loss of $0.56 per share. Nikola Corporation (NASDAQ: NKLA ) … Full story available on

Benzinga | December 13, 2022

Read More 'AVTE' Stories Here

AVTE Price Returns

1-mo -22.01%
3-mo 20.39%
6-mo -8.49%
1-year 93.32%
3-year N/A
5-year N/A
YTD -22.01%
2022 148.52%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6767 seconds.